Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In CheckMate 9LA, nivolumab plus ipilimumab with chemotherapy prolonged overall survival (OS) versus chemotherapy regardless of tumor PD-L1 expression or histology. We report updated efficacy and safety in all randomized patients with a minimum 4-year follow-up and an exploratory treatment-switching adjustment analysis in all treated patients who received chemotherapy and subsequent immunotherapy. METHODS: alterations, and ECOG performance status ≤1 were randomized 1:1 to nivolumab 360 mg every 3 weeks plus ipilimumab 1 mg/kg every 6 weeks with chemotherapy (two cycles) or chemotherapy (four cycles, with optional maintenance pemetrexed for the nonsquamous population). Assessments included OS, progression-free survival, and objective response rate. Exploratory analyses included efficacy by tumor PD-L1 expression and histology and in patients who discontinued nivolumab plus ipilimumab with chemotherapy due to treatment-related adverse events (TRAEs), and a treatment-switching adjustment analysis using inverse probability of censoring weighting. RESULTS: With a 47.9-month minimum follow-up for OS, nivolumab plus ipilimumab with chemotherapy continued to prolong OS over chemotherapy in all randomized patients (HR 0.74, 95% CI 0.63 to 0.87; 4-year OS rate: 21% versus 16%), regardless of tumor PD-L1 expression (HR (95% CI): PD-L1<1%, 0.66 (0.50 to 0.86) and ≥1%, 0.74 (0.60 to 0.92)) or histology (squamous, 0.64 (0.48 to 0.84) and non-squamous, 0.80 (0.66 to 0.97)). In patients who discontinued all components of nivolumab plus ipilimumab with chemotherapy due to TRAEs (n=61), the 4-year OS rate was 41%. With treatment-switching adjustment for the 36% of patients receiving subsequent immunotherapy in the chemotherapy arm, the estimated HR of nivolumab plus ipilimumab with chemotherapy versus chemotherapy was 0.66 (95% CI 0.55 to 0.80). No new safety signals were observed. CONCLUSIONS: In this 4-year update, patients treated with nivolumab plus ipilimumab with chemotherapy continued to have long-term, durable efficacy benefit over chemotherapy regardless of tumor PD-L1 expression and/or histology. A greater estimated relative OS benefit was observed after adjustment for subsequent immunotherapy use in the chemotherapy arm. These results further support nivolumab plus ipilimumab with chemotherapy as a first-line treatment for patients with metastatic/recurrent NSCLC, including those with tumor PD-L1<1% or squamous histology, populations with high unmet needs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Reck, M., Rodríguez–Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00149 · Cited by 1,670
Self-citationPaz-Ares, L., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30641-0 · Cited by 1,366
Self-citationReck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00174 · Cited by 1,159
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02229 · Cited by 1,117
Robins, J. M., & Finkelstein, D. M. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00779.x · Cited by 877
Garassino, M. C., Gadgeel, S., Speranza, G., Felip, E., Esteban, E., Dómine, M., Hochmair, M. J., Powell, S. F., Bischoff, H. G., Peled, N., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01989 · Cited by 733
Self-citationHendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.013 · Cited by 620
Novello, S., Kowalski, D. M., Luft, A., Gümüş, M., Vicente, D., Mazières, J., Rodríguez-Cid, J., Tafreshi, A., Cheng, Y., Lee, K. H., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01990 · Cited by 556
Marginal Structural Models versus Structural nested Models as Tools for Causal inference
Robins, J. M. (2000) · The IMA Volumes in Mathematics and its Applications · doi:10.1007/978-1-4612-1284-3_2 · Cited by 550
Research works printed but not linked: 2
- O’Byrne K , Popoff E , Badin F , et al . Efficacy of nivolumab + ipilimumab versus other first-line treatments for metastatic NSCLC with PD-L1 <1%: a network meta-analysis. presentation at the IASLC world conference on lung cancer; September 9–12, 2023; Singapore. Available: https://cattendee.abstractsonline.com/meeting/10925/Session/183 [Accessed 22 Sep 2023].
- Ramalingam S , Ciuleanu TE , Caro RB , et al . Oral presentation at the IASLC world conference on lung cancer; September 9–12, 2023; Singapore. Abstract OA14.03.
Cited by
Hendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00551-9 · Cited by 568
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Reck, M., Ciuleanu, T., Schenker, M., Bordenave, S., Cobo, M., Juan, Ó., Reinmuth, N., Richardet, E., Felip, E., Menezes, J. J. D., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114296 · Cited by 120
Wang, Y., Safi, M., Hirsch, F. R., Lu, S., Peters, S., Govindan, R., Rosell, R., Park, K., & Zhang, J. J. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00979-8 · Cited by 84
“Both ipilimumab (plus nivolumab with or without chemotherapy) and tremelimumab (plus durvalumab and chemotherapy) have been demonstrated to provide significant improvements in OS versus chemotherapy 15,42,43 .”
InfluentialShiraishi, Y., Nomura, S., Sugawara, S., Horinouchi, H., Yoneshima, Y., Hayashi, H., Azuma, K., Hara, S., Niho, S., Morita, R., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00185-1 · Cited by 62
Metadata
- Authors
- Carbone, D. P., Ciuleanu, T.-E., Schenker, M., Cobo, M., Bordenave, S., Juan-Vidal, O., Menezes, J., Reinmuth, N., Richardet, E., Cheng, Y., Mizutani, H., Felip, E., Zurawski, B., Alexandru, A., Paz-Ares, L., Lu, S., John, T., Zhang, X., Mahmood, J., Hu, N., De, T., Santi, I., Penrod, J. R., Yuan, Y., Lee, A., & Reck, M.
- Affiliations
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Iuliu Hațieganu University of Medicine and Pharmacy (RO)
- Department of Medical Oncology, SF Nectarie Oncology Center, Craiova, Romania
- Hospital Clínico Universitario Virgen de la Victoria (ES)
- Institut du Thorax (FR)
- Department of Medical Oncology, Hospital Universitario La Fe, Valencia, Spain
- Grupo Hospitalar Conceição (BR)
- German Center for Lung Research (DE)
- Instituto Oncológico de Córdoba (AR)
- Jilin Province Tumor Hospital (CN)
- Saitama Cancer Center (JP)
- Vall d'Hebron Hospital Universitari (ES)
- Chemotherapy Department, Ambulatorium Chemioterapii, Bydgoszcz, Poland
- Institutul Oncologic Bucuresti (RO)
- Universidad Complutense de Madrid (ES)
- Shanghai Jiao Tong University (CN)
- Austin Hospital (AU)
- Bristol-Myers Squibb (United States) (US)
- PAREXEL International (United States) (US)
- Corresponding author
- Carbone, David P.
- ORCID
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2024-02
- Volume
- 12
- Issue
- 2
- Pages
- e008189
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC10862253
- OpenAlex
- W4391743853
- Cited by
- 65
- References
- 38
- Citations by year
- 2026: 13 · 2025: 26 · 2024: 26
- FWCI
- 11.06
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc)
- Funders
- Bristol Myers Squibb (N/A)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- metastatic non-small cell lung cancer, nivolumab, ipilimumab, immune checkpoint inhibitors, combination immunotherapy, chemotherapy, PD-L1 expression, treatment switching, overall survival, progression-free survival, objective response rate, treatment-related adverse events, inverse probability of censoring weighting, long-term follow-up, lung squamous cell carcinoma, non-squamous cell lung cancer, treatment discontinuation
- MeSH terms
- Ipilimumab, Nivolumab, Treatment Switching, Adult, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Humans, Lung Neoplasms, Neoplasm Recurrence, Local, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial. https://app.cochat.ai/papers/10.1136/jitc-2023-008189
- The paper
- Carbone, D. P., Ciuleanu, T.-E., Schenker, M., Cobo, M., Bordenave, S., Juan-Vidal, O., Menezes, J., Reinmuth, N., Richardet, E., Cheng, Y., Mizutani, H., Felip, E., Zurawski, B., Alexandru, A., Paz-Ares, L., Lu, S., John, T., Zhang, X., Mahmood, J., . . . Reck, M. (2024). Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-008189
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.